USFDA issues CRL for proposed biosimilar Insulin Aspart: Biocon
Sanofi`s Truvelog Mix 30 (insulin aspart) Approved In Europe
Novo Nordisk's Biologic Fiasp Penfill(Insulin aspart) Receives Approval in the U.S.
Novo Nordisk's Biologic Fiasp FlexTouch (Insulin aspart) Receives Approval in the U.S.
Novo Nordisk's Biologic Fiasp (Insulin aspart) Receives Approval in the U.S.
March 14 (Reuters) - Novo Nordisk (NOVOb.CO) said on Tuesday it would cut U.S. list prices for several insulin products by up to 75% next year, joining rival Eli Lilly and Co (LLY.N) as political pressure mounts to make these life-sustaining diabetes treatments more affordable.
Novo's Biologic Ryzodeg (Insulin aspart & insulin degludec ) Receives Approval in the U.S.
sanofi-aventis groupe Truvelog Mix 30(insulin aspart) Receives Approval in Europe
New Delhi, Jan 7 (PTI) Biocon Biologics, a subsidiary of biotechnology major Biocon, on Friday said the US health regulator has not approved an application for Insulin Aspart filed by its partner Viatris Inc.
Bagsværd, Denmark, 26 November 2021n– Novo Nordisk today announced that the company has received the nresults from the Volume Based Procurement (VBP) tender for insulin in nChina. The Chinese National Healthcare Security Administration has ntendered insulin sold at hospitals, and Novo Nordisk has participated innthe tender. All Novo Nordisk’s insulin were included in the tender nexcept for Ryzodeg® and Xultophy®.